Biotech News

Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue

Organogenesis (ORGO)Organogenesis2026-02-26 21:05 ESTEarnings

CANTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports

Organogenesis

Regenerative Medicine Organogenesis develops and manufactures regenerative-medicine products used to support healing in difficult wounds and surgical procedures. Advanced Wound Care The company's wound-care portfolio includes cellular and tissue-based products, placental-derived products and other biologic matrices used in chronic and...

Recent company news

ORGOOrganogenesis2026-08-06 20:05 EST

Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results

ORGOOrganogenesis2026-07-27 20:05 EST

Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers

ORGOOrganogenesis2026-07-09 11:30 EST

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026

ORGOOrganogenesis2026-07-06 20:05 EST

Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis

ORGOOrganogenesis2026-05-07 20:06 EST

Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results

Stock data

Close: 1.80 USD
Market cap: 288.23M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States